Corporate News Releases

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the H.C. Wainwright Global Life Sciences Conference Being Held Virtually March 9-10, 2021
ZyVersa Therapeutics' CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in the 39th Annual J.P. Morgan Healthcare Conference 2021, January 11th - 14th
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020
Review Article, Authored by ZyVersa Therapeutics' Esteemed Scientific Advisors, Demonstrates the Role of Inflammasomes in the Exacerbated Immune Response Associated with COVID-19 Infection (Just Published in Frontiers in Immunology)
Journal of Neuroinflammation Article Highlights the Role of Inflammasomes in the Pathogenesis of Multiple Sclerosis, and Mentions the Potential for ASC Inhibitor, IC 100, to Interfere with Inflammasome Signaling at Multiple Points in the Inflammatory Pathway
Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis
ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch
ZyVersa Therapeutics Releases Video Demonstrating How Inflammasomes Stimulate and Perpetuate Inflammation, and How a Novel Inflammasome Inhibitor, IC 100, Has Potential to Control Chronic Damaging Inflammation Associated with Inflammatory Diseases
ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020